U.S., May 21 -- ClinicalTrials.gov registry received information related to the study (NCT06980142) titled 'A Study of CM512 in Subjects With Moderate-to-Severe Chronic Obstructive Pulmonary Disease' on May 12.
Brief Summary: A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase II Study to Explore the Efficacy and Safety of CM512 Injection in Adults with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
Study Start Date: June 20
Study Type: INTERVENTIONAL
Condition:
Chronic Obstructive Pulmonary Disease
Intervention:
BIOLOGICAL: CM512
Administered SC
DRUG: Placebo
Administered SC
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Keymed Biosciences Co.Ltd
Published by HT Digital Content Services with...